Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis

NCT03758443 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT03758443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03758443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
Lead sponsor
Theravance Biopharma
Phase
Phase 2/3
Overall status
Terminated
Start date
March 11, 2019
Completion date
October 20, 2021
Enrollment
239 (actual)
Sites
188

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)